AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $347.82
- 52-wk high
- $385.22
- High
- $351.94
- 52-wk low
- $253.95
- Low
- $346.17
- Prev close
- $351.48
- Mkt cap
- $39.71B
- P/E
- 62.8x
- Volume
- 674.7K
- Fwd P/E
- 33.9x
- Beta
- 0.52
- P/S
- 6.5x
- P/B
- 7.7x
- Profit margin
- +10.7%
- Op margin
- +19.1%
- ROE
- +14.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in 46.4% above what analysts expected.
Earnings per share
$1.40 expected
What the street expects next
EPS expected
$1.56 to $2.11
Revenue expected
12 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.41B | $1.50B | $1.51B | $1.71B |
| Cost of what it sold | $196.5M | $142.4M | $167.2M | $174.5M |
| Gross profit | $1.22B | $1.36B | $1.35B | $1.53B |
| What it spent | ||||
| Research and development | $523.7M | $615.4M | $541.2M | $612.3M |
| Sales and admin | $529.0M | $555.3M | $555.1M | $593.2M |
| Total operating expenses | $1.05B | $1.17B | $1.10B | $1.21B |
| What was left | ||||
| Operating profit | $163.1M | $185.0M | $249.9M | $325.0M |
| Interest on debt | — | $58.2M | $32.9M | $39.7M |
| Profit before tax | $147.2M | $149.2M | $259.2M | $312.5M |
| Tax | $22.3M | $82.7M | $31.9M | $75.5M |
| Net profit | $124.8M | $66.5M | $227.4M | $237.0M |
| EBITDA | $184.4M | $249.0M | $333.2M | $392.7M |
Technicals
Price structure
This stock's price action is mixed, and looks oversold after a sharp drop.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
BeiGene H1 net profit surges 627% as global Zanubrutinib sales top 16.1 billion yuan
BullishAug 30Earnings Preview: BeiGene to Report Financial Results Pre-market on August 27
NeutralAug 26BeOne Medicines receives FDA approval for TEVIMBRA and ZIIHERA regimen
BullishAug 25RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $450
BullishAug 25